Dihydroergosine pharmacokinetic modelling and simulation.
For this study of dihydroergosine pharmacokinetic modelling and simulation, the data from our paper about 3H-DHESN plasma, bile, urine, and faeces concentrations after intravenous and oral administration were used (1). The model obtained with the identified parameters was in agreement with in vivo data. Certain special phenomena, such as the enterohepatic cycle and incomplete absorption, were taken into account. Analog-hybrid simulation and identification represents an effective tool for such studies. In spite of the limited validity of the available in vivo data, the work represents a first step in the introduction of DHESN into human medicine.
D000284:Administration, Oral; D001646:Bile / Q000378:metabolism; D003201:Computers; D004879:Ergotamines / Q000378:metabolism*; D005243:Feces / Q000032:analysis; D007275:Injections, Intravenous; D007700:Kinetics; D008954:Models, Biological; D013997:Time Factors
D004879:Ergotamines; C037580:9,10-dihydroergosine